Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0409974 (lupus)
 22,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Blood glutathione-peroxidase (GSH-Px) was determined in 61 healthy subjects and 506 patients with various skin disorders. Depressed levels were observed in patients with psoriasis, eczema, atopic dermatitis, vasculitis, mycosis fungoides and dermatitis herpetiformis. Low values of GSH-Px were also found in some patients with pemphigoid, acne conglobata, polymyositis, rheumatoid arthritis, scleroderma and systemic lupus erythematodes. Vegetarian diet, malnutrition and alcohol abuse could possibly account for the low values in some patients. Fifty patients with low GSH-Px levels were treated with tablets containing 0.2 mg selenium as Na2SeO3 and 10 mg tocopheryl succinate. The GSH-Px levels increased slowly within 6-8 weeks of treatment. The clinical effect was encouraging and calls for controlled studies.
 ...
PMID:Blood glutathione-peroxidase levels in skin diseases: effect of selenium and vitamin E treatment. 617 60

Plasma exchange, used since 1979 in the treatment of severe rheumatoid arthritis, has been the subject of numerous publications in the recent years. According to data from a review of the literature and from our personal experience, this therapy cannot be advocated in the usual forms of rheumatoid arthritis. Because of the side-effects, the complicated technical equipment required and the short duration of therapeutic results, plasma exchange should, for the time being, be restricted to malignant forms of rheumatoid arthritis, polyvisceral exacerbations in lupus and scleroderma, and hyperviscosity syndromes in globulinopathies.
 ...
PMID:[Plasma exchange in rheumatology. Technical problems, tolerance, indications]. 630 2

IgG anti-histone antibodies were detected by indirect immunofluorescence in 6 out of 70 sera from rheumatoid arthritis with antinuclear factors, in 1 out of 13 from scleroderma, in 14 out of 25 from spontaneous systemic lupus erythematosus (SLE) and in 11 out of 14 from drug induced lupus. Rheumatoid arthritis patients with IgG anti-histone antibodies were characterized by the severity of joint involvement and by the high frequency of extraarticular features of the disease. SLE patients with anti-histone antibodies only differed from patients without such antibodies by a higher frequency of Raynaud phenomenon (p less than 0.05). Longitudinal studies of spontaneous SLE showed that IgG anti-histone antibodies correlated with disease activity (p less than 0.001). A significant correlation was demonstrated between anti-histone IgGs and anti-ds-DNA antibodies assessed by the Farr binding assay (p less than 0.0001). IgG anti-histone antibodies were rarely found in sera from patients with drug induced antinuclear antibodies without symptoms of SLE (1 out of 6 sera). In drug induced lupus, IgG anti-histone antibodies were found in the absence of high titers of anti-ds-DNA antibodies, and this discrepancy appeared to suggest the diagnosis of drug induced lupus. Finally, anti-histone antibodies were present in 5 out of 7 sera from acebutolol induced lupus.
 ...
PMID:[IgG-type antihistone antibodies. Diagnostic value in rheumatoid polyarthritis, scleroderma, spontaneous and drug-induced lupus]. 638 65

Sera from 98 patients were examined for antinuclear antibodies (ANA). The patient population has been previously identified clinically as having the following diseases: systemic lupus erythematosus, scleroderma, dermato or polymyositis, discoid lupus, rheumatoid arthritis, Raynaud phenomena only, undifferentiated connective tissue disease, and psoriasis. All sera samples were tested using both HEp-2 cells and rat kidney tissue as substrates and were stained with both fluorescein-conjugated antihuman antibody and glucose oxidase-conjugated antibody to human IgG. Each serum was initially tested at a screening dilution of 1:40 with PBS. Positive sera were serially diluted until an end point was observed. The number of dilutions for each specimen in all four combinations was compared mathematically using the Pearson product moment correlation. Using this method, glucose oxidase- and fluorescein-conjugated antinuclear antibody (FANA) techniques appear to have a high positive correlation (r = 0.92 kidney, r = 0.95 Hep-2) in this patient population. In our experience, the glucose oxidase technique offers comparable results to FANA and is ideally suited for the hospital laboratory, especially facilities without the benefit of a fluorescent microscope.
 ...
PMID:A comparative study of glucose oxidase versus FITC-labeled antibody techniques for the detection of antinuclear antibodies. 643 30

Human graft-versus-host disease (GVHD) has several cutaneous manifestations, including a lichenoid and a sclerotic injury pattern. A versatile animal model of graft-versus-host skin disease (GVHSD) would facilitate study of the pathophysiology of these two cutaneous injury patterns. We have examined two murine chimeras histologically and have found two distinct patterns. Allogeneically transplanted B1/6 mice show a prolonged lichenoid-interface dermatitis that eventuates in clinical alopecia, whereas LP/J recipients of allogeneic cells do not show hair loss. Their histopathology consists of an early lichenoid phase that abates and is replaced by dermal sclerosis. Because of the versatility of the mouse as a laboratory animal, we feel that this model provides an excellent opportunity to define the immunopathologic mechanisms responsible for skin injury in GVHD. In addition, an understanding of the pathogenesis of the T cell-dependent, lichenoid, and sclerotic patterns of tissue injury in GVHSD might well provide insight into the pathogenesis of the GVHSD analogs, cutaneous lupus erythematosus and scleroderma.
 ...
PMID:Murine graft-versus-host skin disease: a chronologic and quantitative analysis of two histologic patterns. 663 Oct 52

Antinuclear antibody (ANA) test results were correlated with the clinical status of 56 patients with systemic scleroderma. Three groups were identified. (1) The speckled pattern represented a benign clinical subset. Acrosclerosis, Raynaud's phenomenon, calcinosis, and esophageal dysmotility characterized this group. None of these patients had pulmonary, renal, or cardiac disease. (2) Two patterns and ANA-negative test results were associated with a different incidence of certain clinical characteristics. The thready pattern was associated with pulmonary involvement. Diffuse skin involvement and Raynaud's phenomenon were found with the nucleolar pattern. Patients with ANA-negative test results had the most severe disease, including renal failure. (3) Two patterns were not associated with different clinical characteristics. These were the small speckle-like thready pattern and the homogeneous pattern. This study supports the theory that ANA patterns may be used as immunologic markers for different clinical characteristics of patients with scleroderma as they have already been used in lupus erythematosus.
 ...
PMID:Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma. 675 66

The results of investigations for antinuclear antibodies in scleroderma and other connective diseases are reported. An indirect fluorescence method on Hep-2 cell smears was used. Antibodies directed against chromosomal centromeres were detected in 25 cases: 19 sera of patients with diffuse scleroderma, 2 cases of Raynaud's disease, 2 cases of rheumatoid arthritis and 1 case each of lupus and dermatomyositis. A significant correlation was found between the presence of anticentromere antibodies and benign forms of scleroderma, notably the CREST syndrome.
 ...
PMID:[Anticentromere antibodies. Diagnostic and prognostic value]. 675 88

Use of an immunoenzyme technique to seek two types of antibody (AB): antihistones and bicatenary anti-RNA, led to study of their distribution in different connective tissue and autoimmune diseases. Total antihistone AB and the H1 and H2b antifractions were seen almost exclusively in lupus (52.5 per cent of cases), principally during active phases of the disease since 87 per cent of active forms had antihistone AB as against 15 per cent of inactive forms. Antihistone AB would thus appear to be a valuable laboratory investigation in the diagnosis and surveillance of lupus. Bicatenary anti-RNA AB were more widely distributed, being found in DLE, RA, scleroderma and in various disorders with antinuclear antibodies. However they were slightly more common in active forms of lupus and their titres appeared to fall more quickly than those of antinuclear AB and anti-DNA AB at the time of clinical improvements. In RA, bicatenary anti-RNA AB were more commonly associated with inflammatory and progressive forms but further studies involving larger populations would be necessary to confirm these findings.
 ...
PMID:[Study of antihistone and anti-bicatenary RNA antibodies in connective tissue diseases using immunoenzyme technic]. 710 Aug 7

A method for performing capillary microscopy using an ophthalmoscope is described. Using this technic, we examined 130 patients with various connective tissue diseases. As in prior studies, four patterns could be discerned; scleroderma (SD) pattern, lupus erythematosus (LE) pattern, normal pattern, and a nonspecific pattern. Of the patients with systemic SD, 70% had SD pattern. Of LE patients, 53% had LE pattern. There was little crossover. It is hoped that the use of the ophthalmoscope will result in the widespread use of capillary microscopy.
 ...
PMID:Office nail fold capillary microscopy using ophthalmoscope. 713 Apr 82

The pharmacology of the most important immunosuppressive agents in dermatology: glucocorticoids, azathioprine, cyclophosphamide, methotrexate and chlorambucil are reviewed. Our own results of treatment with these drugs (102 patients, diagnosis: lupus erythematosus, dermatomyositis, scleroderma, overlap-syndrome, pemphigus vulgaris, bullous pemphigoid, cryoglobulinaemic purpura, and pyoderma gangraenosum) are presented.
 ...
PMID:[Medicamental immunosuppression in dermatology (author's transl)]. 726 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>